We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work.
Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment
Aaron D. Fox , Adam Chamberlain , Taeko Frost , Chinazo O. Cunningham
Substance Abuse
Vol. 36, Iss. 2, 2015
Our study demonstrates high levels of interest among harm reduction agency clients in initiating buprenorphine maintenance treatment onsite at harm reduction agencies. In the United States, harm reduction agencies already provide diverse services, including sterile syringe exchange, to people who use drugs, and they reach a unique population who may not use traditional medical or drug treatment services. Providing buprenorphine treatment onsite could better reach those in need of opioid addiction treatment than traditional approaches.